Global Defense Contractor Burke Products Selects Datavault AI for Enhanced National Defense and Aerospace Technologies Contracts
Datavault AI Inc. (NASDAQ: DVLT)
, a leader in data visualization, valuation, and monetization technologies, today announced a strategic partnership with Burke Products ('Burke'), a minority-owned Tier 1 supplier to Lockheed Martin, Raytheon Technologies, Department of Defense, Original Equipment Manufacturers (OEMs), and the Defense Logistics Agency as well as their international allied force corollaries. The partnership stands to deliver 2025 Revenues from existing contracts of Burke's that have now been subcontracted to Datavault AI and is set to scale into productized offerings into 2026.
Within the partnership Datavault AI has been contracted by Burke Products to engineer and produce solutions responsive to an array of opportunities. All opportunities are managed under the contract in a case by case fashion designed to be responsive to private and public RFPs and requests made directly and through subcontracts obtained by Burke and other contracting mechanisms in place at Burke Products on a global basis.
Military grade engineering, manufacturing and productization is now underway. The collaboration aims to advance defense and aerospace capabilities by integrating Datavault AI's services and proprietary data and ADIO® tone technologies with Burke's experienced manufacturing and engineering teams to accelerate productization and speed to market that Datavault AI's technologies have been designed to automate and support at scale.
According to Janes, global defense spending is projected to exceed $2.2 trillion in 2025, with the U.S. defense budget alone expected to surpass $900 billion. As modernization efforts escalate, the sector is increasingly focused on secure data solutions, advanced tracking, and predictive intelligence—areas where Datavault AI is uniquely positioned to deliver for Burke new and innovative solutions that solve for advantages and forward progression of technologies in this sector. With Web 3.0 centric contributions of Datavault AI this partnership will explore technological synergies with particular emphasis on secure data management, resource tracking, and communication systems critical to mission success.
Aaron Bakhshi, CEO of Burke Products, shared his outlook on the business alliance and licensing contracts now in place with Datavault AI, 'For more than 59 years, Burke Products has supplied advanced electro-mechanical components and assemblies to leading defense and aerospace partners, including Lockheed Martin, Raytheon Technologies, Northrop Grumman, General Dynamics, the U.S. Navy, the Defense Logistics Agency, and their allied international counterparts. As a minority-owned defense contractor committed to engineering innovation, we view this strategic alliance with Datavault AI as a transformative step toward future-ready solutions. The introduction and demonstrations of Datavault's solutions into our product portfolio marks a significant evolution in how we approach innovation across mission-critical systems.'
Bakhshi continued: 'This collaboration originated from Sonia Choi's ability to identify and align mutual strategic interests, particularly around innovations in acoustic sciences and separately, the urgent challenge of addressing stolen valor—two distinct areas where Datavault AI's platform provides an elegant and effective solution. Additionally, our shared vision around the scalable deployment of Digital Twin technologies further strengthens the foundation of this partnership and unlocks significant future potential. Her skill in connecting advanced technology to real-world defense applications and viable business models was instrumental in forming this agreement. It resonates with me, as it reflects the executive vision and innovation that Burke Products strives to champion across all of our initiatives. We believe the work underway with Datavault AI will deliver measurable value to our clients and help redefine operational standards across multiple defense verticals with new Web 3.0 solutions.'
The first phase will integrate Datavault AI's acoustic sciences services and products, including patented ADIO® tone technology, into Burke's pre-existing systems. Future phases may expand into integrating Datavault AI's proprietary data solutions for digital twin modeling, predictive analytics, inventory logistics and management as well as blockchain-based tools to secure supply chains and authenticate critical components throughout their lifecycle.
'It has been an honor to work with and partner alongside Aaron Bakhshi and Burke Products to help extend Datavault AI's orchestrated blend of talent and technological footprint into the defense sector,' said Sonia Choi, Co-Founder and CMO of Datavault AI and Lead Principal Investigator on a privately funded Strategic Partnership Project facilitated through the U.S. Department of Energy's Brookhaven National Laboratory.
'Burke Products has a rare and profound legacy of combining engineering precision with innovation—qualities that immediately resonated with our shared commitment to mission-critical performance. We are both builders and systems thinkers, capable of harnessing our technologies to automate high-value solutions in environments defined by complexity and zero tolerance for error. By leveraging our advanced data and acoustic sciences to solve real-world problems and by aligning our ecosystems together, we're laying the groundwork for scalable, American-built solutions. This marks a pivotal step and underscores Datavault AI's strategic entry into, and sustained relevance within, modern defense infrastructure,' stated Sonia Choi.
As the defense and aerospace sectors rapidly evolve, this partnership marks a significant milestone. With a focus on security, precision, and next-gen data integration, Datavault AI and Burke Products are working together to shape the future of national defense technology.
Nathaniel T. Bradley, Co-Founder and CEO of Datavault AI, asserted: 'This collaboration marks an international milestone of a scale we couldn't have anticipated when we first founded the company. Sonia Choi has been diligently building toward this moment for years, and her ability to identify high-impact applications for Datavault AI's technologies—while guiding our team through the execution with focus and discipline—has been exceptional. Through her vision and leadership, we've reached a breakthrough that aligns seamlessly across our VerifyU, ADIO®, High Performance Computing, WiSA and Datavault platforms, in concert with Burke Products' expansive capabilities, trusted network, and precision-driven engineering excellence.'
Bradley noted, 'Together, with Burke Products, we now have an industry leading, solutions-oriented contracting partner that not only understands Datavault AI's mission, but is equipped to deliver defense-grade, purpose-built innovations when they are most needed. Sonia's and Aaron's influence will have a lasting impact—not only on Datavault AI's trajectory, but on the broader U.S. defense industry it serves. We're deeply grateful to Burke Products for validating our intellectual property, recognizing the strength of our team, and stepping forward with us to realize the full potential of this partnership.'
About Datavault AI Inc.
Datavault AITM (Nasdaq: DVLT) is leading the way in AI driven data experiences, valuation and monetization of assets in the Web 3.0 environment. The company's cloud-based platform provides comprehensive solutions with a collaborative focus in its Acoustic Science and Data Science Divisions. Datavault AI's Acoustic Science Division features WiSA®, ADIO® and Sumerian® patented technologies and industry-first foundational spatial and multichannel wireless HD sound transmission technologies with IP covering audio timing, synchronization and multi-channel interference cancellation. The Data Science Division leverages the power of Web 3.0 and high-performance computing to provide solutions for experiential data perception, valuation and secure monetization. Datavault AI's cloud-based platform provides comprehensive solutions serving multiple industries, including HPC software licensing for sports & entertainment, events & venues, biotech, education, fintech, real estate, healthcare, energy and more. The Information Data Exchange® (IDE) enables Digital Twins, licensing of name, image and likeness (NIL) by securely attaching physical real-world objects to immutable metadata objects, fostering responsible AI with integrity. Datavault AI's technology suite is completely customizable and offers AI and Machine Learning (ML) automation, third-party integration, detailed analytics and data, marketing automation and advertising monitoring. The company is headquartered in Beaverton, OR. Learn more about Datavault AI at
www.dvlt.ai
.
About Burke Products, Inc.
Burke Products, Inc. is a minority-owned manufacturer of high-precision electro-mechanical components and assemblies, serving the aerospace and defense sectors for over 59 years. The company has established a longstanding reputation for reliability and excellence across critical supply chains, maintaining established relationships with clients including the U.S. Department of Defense, Defense Logistics Agency (DLA), Lockheed Martin, Raytheon Technologies, Honeywell, General Dynamics, Goodrich, and Johnson & Johnson. Internationally, Burke has fulfilled government contracts and procurement programs for India and our allied defense partners in the UK, Japan, Germany, Turkey, and many others. Operating under ISO and AS-compliant quality systems, Burke specializes in contracted manufacturing, acoustic systems and technology integration, and rapid design-to-production capabilities for defense-grade hardware. Its core competencies support both domestic and allied military readiness through scalable, high-integrity supply partnerships.
To learn more about Burke Products, please visit
https://burkeproducts.com/
.
Cautionary Note Regarding Forward-Looking Statements
This press release contains 'forward-looking statements' within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, and other securities laws. Words such as 'expect,' 'will,' 'anticipates,' 'estimates' and variations of such words and similar future or conditional expressions are intended to identify forward-looking statements. Such forward-looking statements, including statements herein regarding our business opportunities and prospects, strategy, future revenue expectations, licensing initiatives, recent funding and M&A activities as well as our plans to integrate acquired businesses and technologies, are necessarily based upon estimates and assumptions that, while considered reasonable by us and our management, are inherently uncertain. Readers are cautioned not to place undue reliance on these forward-looking statements. Actual results may differ materially from those indicated by these forward-looking statements as a result of various risks and uncertainties including, but not limited to, the following: the risk that we are unable to satisfy all closing conditions in connection with the senior notes issuance described above, and the acquisition of certain assets from CSI; our ability to successfully integrate all IP that we have acquired; risks regarding our ability to utilize the assets we acquire to successfully grow our market share; risks regarding our ability to open up new revenue streams as a result of the various agreements we have entered into and assets we have acquired; our current liquidity position and the need to obtain additional financing to support ongoing operations; general market, economic and other conditions; our ability to continue as a going concern; our ability to maintain the listing of our common stock on Nasdaq; our ability to manage costs and execute on our operational and budget plans; our ability to achieve our financial goals; the degree to which our licensees implement the licensed technology into their products, if at all; the timeline to any such implementation; risks related to technology innovation and intellectual property, and other risks as more fully described in our filings with the U.S. Securities and Exchange Commission. The information in this press release is provided only as of the date of this press release, and we undertake no obligation to update any forward-looking statements contained in this communication based on new information, future events, or otherwise, except as required by law.
Investors:
Alliance Advisors Investor Relations
datavaultinvestors@allianceadvisors.com
Marketing Inquiries:
marketing@vault.email
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
2 minutes ago
- Yahoo
TransMedics Group Inc (TMDX) Q2 2025 Earnings Call Highlights: Record Revenue Growth and ...
Release Date: July 30, 2025 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Positive Points TransMedics Group Inc (NASDAQ:TMDX) reported a 38% year-over-year revenue growth for Q2 2025, reaching $157.4 million. The company achieved a new high water mark for clinical cases and revenue, demonstrating significant operating leverage. TransMedics Group Inc (NASDAQ:TMDX) maintained a steady gross margin of 61.4% in Q2 2025. The company added approximately $90 million to its balance sheet, ending Q2 with over $400 million in cash. TransMedics Group Inc (NASDAQ:TMDX) received FDA conditional approval for the OCS lung IDE and is on track to launch both heart and lung clinical programs before year-end. Negative Points There is market confusion and noise following comments made by a competitor in the organ preservation ecosystem. The company anticipates some minor and transient seasonality in Q3 performance due to summer vacation season. Operating expenses increased by 6% year over year, driven by a 50% increase in R&D expenses. The company faces potential challenges from the US National Transplant modernization initiative, which could impact smaller market players. There is ongoing concern about the impact of oversight on DCD usage, which could affect the company's operations. Q & A Highlights Warning! GuruFocus has detected 4 Warning Sign with TMDX. Q: Can you provide insights on the seasonality impact observed in July and how it compares to last year? A: We are seeing some signs of seasonality, similar to last year, but slightly less pronounced. However, it's still early in the quarter, and we expect some seasonality in Q3 due to various factors. Overall, the impact seems to be slightly less than last year, but it's too early to establish a trend. - Walid Hassanein, President and CEO Q: Are there any concerns about the impact of increased oversight on DCD usage following recent media coverage? A: We believe that some level of oversight could actually benefit the transplant market, especially in DCD. The lack of oversight has led to inefficiencies and lost opportunities for organ preservation. We are confident that our business model can operate effectively in both the current and any future systems. - Walid Hassanein, President and CEO Q: Were there any changes to the lung trial design after discussions with the FDA? A: The clinical trial design remains unchanged. Most of the remaining questions from the FDA are focused on pre-clinical testing. We plan to publish the full design of the clinical program on in late August or early September. - Walid Hassanein, President and CEO Q: What are your thoughts on the US heart market, given the recent flat trend in volumes? A: The heart market has experienced ebbs and flows due to waiting list dynamics. We expect the market to rebound, especially with the introduction of our next-gen heart technology. The growth of DCD and other factors may have temporarily impacted volumes, but we see this as a transient phenomenon. - Walid Hassanein, President and CEO Q: How do you see the NextGen OCS platform impacting lung transplants? A: The NextGen OCS platform is designed to address historical concerns in the US lung perfusion market, such as lung edema and perfusion limitations. We aim to prove the superiority of our platform over cold storage with level one evidence, potentially establishing it as the next standard of care. - Walid Hassanein, President and CEO For the complete transcript of the earnings call, please refer to the full earnings call transcript. This article first appeared on GuruFocus. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
2 minutes ago
- Yahoo
Western Digital Corp (WDC) Q4 2025 Earnings Call Highlights: Strong Revenue Growth and ...
Revenue: $2.6 billion, up 30% year-over-year. Non-GAAP Gross Margin: 41.3%, improved by 610 basis points year-over-year. Non-GAAP Earnings Per Share (EPS): $1.66, up 22% sequentially. Free Cash Flow: $675 million for the quarter. Debt Reduction: Lowered by $2.6 billion during the quarter. Operating Expenses: $345 million. Operating Income: $732 million, with an operating margin of 28.1%. Interest and Other Expenses: $52 million. Cash and Cash Equivalents: $2.1 billion at the end of the fiscal fourth quarter. Share Repurchase: $149 million worth of shares repurchased. Quarterly Cash Dividend: $0.10 per share, resulting in $36 million of dividend payments. Cloud Revenue: $2.3 billion, representing 90% of total revenue, up 36% year-over-year. Client Revenue: $140 million, representing 5% of total revenue, up 2% year-over-year. Consumer Revenue: $136 million, representing 5% of total revenue, down 12% year-over-year. Guidance for Q1 Fiscal 2026 Revenue: Expected to be $2.7 billion, plus or minus $100 million. Guidance for Q1 Fiscal 2026 Gross Margin: Expected between 41% and 42%. Guidance for Q1 Fiscal 2026 EPS: Expected to be $1.54, plus or minus $0.15. Warning! GuruFocus has detected 8 Warning Signs with WDC. Release Date: July 30, 2025 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Positive Points Western Digital Corp (NASDAQ:WDC) reported strong financial results for the fourth quarter of fiscal 2025, with revenue of $2.6 billion, up 30% year-over-year. The company achieved a non-GAAP gross margin of 41.3%, reflecting a 610 basis point improvement year-over-year. Western Digital Corp (NASDAQ:WDC) successfully reduced its debt by $2.6 billion, strengthening its balance sheet and achieving a net leverage target range of 1x to 1.5x. The company initiated a quarterly cash dividend program and authorized a $2 billion share repurchase program, demonstrating a commitment to returning cash to shareholders. Demand for high-capacity drives, particularly the latest generation EPMR and UltraSMR drives, is strong, with shipments more than doubling quarter-over-quarter. Negative Points The broader market environment remains uncertain, particularly due to potential tariff impacts and geopolitical tensions. Operating expenses were slightly above guidance due to higher variable compensation, indicating potential challenges in cost management. The company faces risks related to the adoption of new technologies, such as HAMR, which require successful transition and qualification with customers. There is a potential for cyclical downturns in the business, as the company operates in a market that is subject to periods of digestion and fluctuating demand. The ASP per terabyte was down slightly, driven by mix, which could impact revenue growth if not offset by volume increases. Q & A Highlights Q: Can you explain the gross margin guidance for the September quarter and the factors influencing it? A: Kris Sennesael, CFO, explained that the gross margin guidance reflects a stable pricing environment, a favorable mix shift towards higher capacity drives, and effective cost control. The company is executing well on these fronts, and there is confidence in further gross margin improvements over time. Q: With strong free cash flow and reduced debt, how does Western Digital plan to approach share repurchase activity? A: Kris Sennesael, CFO, stated that the company is committed to returning cash to shareholders through dividends and share repurchases. The dividend program has room to grow, and there is no hesitation to execute the share repurchase program as cash flow generation continues to grow. Q: How does the current business structure affect seasonality, especially with 90% of revenue coming from cloud? A: Irving Tan, CEO, noted that traditional seasonality no longer applies as the business is driven by cloud CapEx spend and hyperscale customer programs. While the business is cyclical, the company has good visibility into customer plans, which helps manage potential cycles of digestion. Q: What is the adoption curve for UltraSMR among hyperscale customers, and are there workloads where it is less advantageous? A: Irving Tan, CEO, mentioned that UltraSMR adoption is growing, with a third hyperscale customer recently qualified and a fourth in process. While some legacy workloads use lower capacity drives, new workloads are adopting the highest capacity points available, typically on UltraSMR. Q: How does Western Digital balance capacity planning with customer demand and visibility? A: Irving Tan, CEO, explained that the company educates customers on long lead times and has moved to a 52-week lead time program. This partnership provides insight into growth requirements and helps accelerate aerial density improvements, ensuring the company can meet customer demand without incremental capacity investments. Q: How does the extra week in the fiscal quarter affect revenue and operating expenses? A: Kris Sennesael, CFO, stated that the extra week has minimal impact on revenue but adds approximately $15 million in operating expenses for the quarter. Future quarters will return to normal 13-week periods, reducing operating expenses accordingly. Q: How is agentic AI deployment expected to impact Western Digital's growth projections? A: Irving Tan, CEO, indicated that AI is driving an uplift in exabyte growth, potentially increasing it from the base 15% CAGR to 23%. This, combined with lower ASP declines, could shift revenue growth from mid- to high single digits to mid-teens, enhancing long-term growth prospects. Q: Can you provide an update on the aerial density roadmap leading to HAMR technology? A: Irving Tan, CEO, outlined that the current ePMR products are at 26-terabyte CMR and 32-terabyte UltraSMR. The next generation, qualifying in the first half of 2026, will be 28-terabyte CMR and 36-terabyte UltraSMR. HAMR qualification will start in the second half of 2027, with a ramp in early 2027, reaching 38-terabyte CMR and 44-terabyte UltraSMR. For the complete transcript of the earnings call, please refer to the full earnings call transcript. This article first appeared on GuruFocus. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
2 minutes ago
- Yahoo
Hologic Inc (HOLX) Q3 2025 Earnings Call Highlights: Surpassing Expectations Amidst Challenges
Total Revenue: $1.024 billion, a slight growth of 0.4%, exceeding guidance by $14 million. Non-GAAP Earnings Per Share (EPS): $1.08, a 1.9% increase year-over-year, exceeding guidance by a penny. Non-GAAP Operating Margin: Just above 30%. Diagnostics Revenue: $448.9 million, 0.9% growth, 2.9% organically excluding COVID-related sales. Breast Health Revenue: $365.2 million, declined 5.8%, 10.8% organically excluding Endomagnetics and SSI. Surgical Revenue: $178.4 million, increased 6.3%, 1.2% organically excluding Gynesonics. Skeletal Revenue: $31.3 million, grew 62.1%. Non-GAAP Gross Margin: 60.3%, an 80 basis points decline year-over-year. Operating Expenses: $309.6 million, increased 2.2%. Net Margin: 23.8%, decreased 100 basis points year-over-year, increased 60 basis points sequentially. Operating Cash Flow: $343 million. Cash and Short-term Investments: $1.88 billion. Net Leverage Ratio: 0.6 times. Fourth Quarter Revenue Guidance: $1.03 billion to $1.04 billion. Fourth Quarter Non-GAAP EPS Guidance: $1.09 to $1.12. Full Year Revenue Guidance: $4.081 billion to $4.091 billion. Full Year Non-GAAP EPS Guidance: $4.23 to $4.26. Warning! GuruFocus has detected 2 Warning Sign with HOLX. Release Date: July 30, 2025 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Positive Points Hologic Inc (NASDAQ:HOLX) exceeded its revenue and non-GAAP earnings per share guidance for the third quarter of fiscal 2025. The diagnostics business showed growth, with molecular diagnostics leading the way, particularly in the United States. The breast health business showed sequential improvement, with positive contributions from the skeletal franchise as supply constraints lifted. Endomagnetics, acquired last summer, contributed nearly $20 million in revenue with a healthy gross margin, exceeding deal expectations. The company has made significant progress in mitigating tariff impacts, reducing expected quarterly tariff expenses by half. Negative Points Breast health revenues declined by 5.8% compared to the prior year, although this was expected. The operating environment in China and reduced funding for HIV tests in Africa negatively impacted the diagnostics business. Non-GAAP gross margin decreased by 80 basis points due to product mix and a reserve recorded in the skeletal health division. Operating expenses increased by 2.2%, driven by acquisitions and increased expenses related to the deferred compensation plan. The company faces ongoing challenges with tariffs, expecting $10 million to $12 million in tariff expenses per quarter in fiscal 2026. Q & A Highlights Q: Are there any dynamics we should consider in our models for fiscal 2026, either tailwinds or headwinds, that could affect the continuation of trends? Also, was there any impact from China DRG in the quarter? A: For fiscal 2026, we expect mid-single-digit growth. Factors to consider include the discontinuation of the flu scan and ongoing headwinds related to China and HIV, which will impact the first half of fiscal 2026. Regarding China DRG, while it hasn't been a significant factor for us, the challenging environment in China has affected our business, with total China revenue down more than 50% compared to the prior year. Q: What are your thoughts on capital allocation, particularly regarding M&A, given the strong cash flow this quarter? A: We have spent over $750 million on buybacks year-to-date and feel good about our actions. We will continue to focus on both M&A and buybacks, but there are no plans for any large acquisitions at this time. Q: Can you discuss the progress and outlook for the breast health business, particularly regarding new product launches and replacement cycles? A: We are optimistic about the breast health business, having addressed previous challenges. We are excited about launching our new product, Vision, which will be significant in the latter half of 2026 and beyond. The interventional business is also becoming a strong driver, contributing to recurring revenue and better margins. Q: How do you view the diagnostic setup for fiscal 2026, considering the growth of molecular diagnostics and BV CV/TV? A: We expect diagnostics to be within the mid-single-digit growth range for fiscal 2026, despite first-half headwinds from China and HIV. The diagnostics business, particularly molecular diagnostics, continues to have significant growth potential, driven by the expansion of Panther systems and new menu offerings. Q: Can you provide more details on the tariff impacts and any further mitigation steps you might take? A: We have successfully mitigated about half of the initially anticipated tariff impacts through operational efficiencies within our supply chain. We continue to evaluate the situation, but for competitive reasons, we won't disclose specific strategies. For the complete transcript of the earnings call, please refer to the full earnings call transcript. This article first appeared on GuruFocus.
